MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling pathway. By targeting a specific subunit of NMDA receptors, they successfully reduced excessive protein synthesis in the brain, a hallmark of the disorder. Their approach, tested in fragile X model mice, not only corrected molecular imbalances but also improved synaptic function and reduced disease symptoms.